Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
Open Access
- 27 April 2022
- journal article
- research article
- Published by American Society for Microbiology in mSphere
- Vol. 7 (2) , e0091521
Abstract
Effective vaccines against SARS-CoV-2 are vital tools for containing the COVID-19 pandemic by increasing population immunity. While currently available vaccines can elicit antibody response against SARS-CoV-2 with high efficacy, the associated side effects may cause vaccine hesitancy.Keywords
Funding Information
- Hong Kong Government (HMRF COVID190124)
- Hong Kong Government (HMRF COVID190125)
This publication has 23 references indexed in Scilit:
- Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent PlasmaThe American Journal of Pathology, 2020
- Development of an inactivated vaccine candidate for SARS-CoV-2Science, 2020
- A comparison study of SARS‐CoV‐2 IgG antibody between male and female COVID‐19 patients: A possible reason underlying different outcome between sexJournal of Medical Virology, 2020
- Comparative Reactogenicity of Enhanced Influenza Vaccines in Older AdultsThe Journal of Infectious Diseases, 2020
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trialThe Lancet, 2020
- The how’s and what’s of vaccine reactogenicitynpj Vaccines, 2019
- Immunogenicity of Intradermal Trivalent Influenza Vaccine With Topical Imiquimod: A Double Blind Randomized Controlled TrialClinical Infectious Diseases, 2014
- Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005)Archives of internal medicine (1960), 2008
- Sex differences in autoimmune diseaseNature Immunology, 2001
- Genetic control of the CD4/CD8 T-cell ratio in humansNature Medicine, 1995